Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan Titov

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
The New England Journal of Medicine|September 27, 2023
Ceftobiprole for Treatment of Complicated <i>Staphylococcus aureus</i> BacteremiaThomas L Holland, Sara E Cosgrove, Sarah B Doernberg, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
The New England Journal of Medicine|September 27, 2023
Ceftobiprole for Treatment of Complicated <i>Staphylococcus aureus</i> BacteremiaThomas L Holland, Sara E Cosgrove, Sarah B Doernberg, et al.
Pageof 2